Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerBilling CodesGenomic Sequencing Procedures and Other Molecular Multianalyte AssaysCPT cpt-81449-tumor-rna-sequencing-panel-5-50-genes
    Ask Trek AI about this page

    CPT 81449: Solid Organ Tumor RNA Panel (5–50 genes)

    Commercial payers pay $560 on average nationally for this procedure.

    CPT code 81449 describes a genomic sequencing panel performed by a laboratory analyst to evaluate a solid organ tumor specimen for RNA alterations across 5 to 50 genes associated with solid organ cancers, representing a molecular diagnostic service typically delivered as a laboratory pathology test on tumor tissue or other appropriate specimen in an inpatient or outpatient laboratory/pathology setting.

    For related coverage guidance, see recent payer policy updates: Minimal Residual Disease (MRD) Testing for Cancer, Biomarker Testing Mandate, Prenatal (Fetal) Diagnostic Testing.

    Customize your policy alerts

    Sign up for cpt 81449 policy alerts

    Get alerted when payer policies referencing 81449 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    National Reimbursement Benchmarks

    National commercial reimbursement for CPT 81449 centers on a BUCA average commercial rate of $560.00, with individual payers showing substantial variation around that midpoint. Blue Cross Blue Shield (BCBS) and Cigna display the highest upper tails, with BCBS max at $2,015.10 and Cigna max at $1,780.90, while Aetna and UnitedHealth Group have lower maximums. Median rates cluster near the BUCA average for some payers but differ meaningfully across insurers, highlighting that commercial payments for this genetic test are uneven across the market.

    Dispersion measured by the interquartile range (P75–P25) is widest for Blue Cross Blue Shield at $252.20, followed by Cigna at $393.50 and BUCA at $313.90; Aetna is the tightest among named payers with an IQR of $142.70, and UnitedHealth Group shows a moderate IQR of $345.80. These differences indicate BCBS and Cigna have the broadest middle-50% spread in allowed amounts, while Aetna’s middle distribution is comparatively concentrated.

    Table of contents

    Progress1 / 9

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools
    National Payer Mean Reimbursement Rates

    State Reimbursement Rates

    State: Alaska1 / 51

    Rate by payer

    Clinical & Coding Specifications

    Clinical Context

    A 64-year-old patient with a history of progressive cough, hemoptysis, and weight loss undergoes bronchoscopy with biopsy of a left bronchial mass. Histopathology confirms non-small cell carcinoma. The oncology team orders a targeted genomic RNA panel to evaluate RNA-based alterations (fusion transcripts, splice variants) across 5–50 genes relevant to solid organ cancers to guide targeted therapy selection and clinical trial eligibility. The clinical workflow: specimen collection in formalin-fixed, paraffin-embedded (FFPE) blocks or fresh frozen tissue → pathology accessioning and review → macrodissection and nucleic acid extraction by the molecular laboratory → library preparation and RNA sequencing or targeted RNA panel testing → bioinformatics analysis and variant calling → laboratory analyst performs genomic sequence analysis, interprets RNA alterations, and generates a report with clinically actionable findings and technical limitations. Turnaround time typically ranges from 7–21 calendar days depending on assay complexity and reflex testing. Insurance preauthorization may be required prior to testing for some payors including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

    Related CPT Codes

    CPT CodeDescriptionRelationship to This Procedure
    81445Genomic sequencing panel, solid organ neoplasm, DNA (5-50 genes)DNA-based genomic panel often ordered alongside or in lieu of RNA panel to detect DNA variants (SNVs, indels, copy number) complementary to RNA fusion detection.

    Related Modifiers

    8 rows

    ModifierDescriptionWhen to Use
    26Modifier 26 (Professional Component) identifies and bills only the professional portion of a split service — the physician’s interpretation, report, and medical judgment — when the technical…- Use CPT Modifier -26 when you are billing only the professional component (PC) of a split‑bill eligible service—i.e., you performed the physician interpretation, medical judgment and prepared a…
    90Modifier ‑90 (Reference/Outside Laboratory) indicates that a laboratory test was performed by an entity other than the treating or reporting provider. The American Medical Association defines…- Use CPT modifier -90 when a laboratory test is performed by an outside/reference laboratory (an entity other than the treating or reporting physician or qualified professional) and the claim needs…
    82Modifier 82 is appended to a surgical CPT code to indicate that an attending physician acted as an assistant because a qualified resident surgeon was unavailable. In teaching hospitals it documents…- When to use: Append modifier 82 in teaching-hospital settings to indicate a physician served as an assistant surgeon because a qualified resident surgeon was unavailable (includes situations where…
    78CPT modifier -78 indicates an unplanned, related return to the operating or procedure room by the same provider during the global postoperative period. It is appended when treatment for a…- Use modifier -78 when an unplanned, related complication during the original procedure’s global postoperative period requires the patient to return to a formal operating or procedure room and the…
    80CPT® Modifier 80 (Assistant Surgeon) is appended to a surgical CPT code when a physician (MD or DO) provides full, continuous assistance throughout the operative procedure. It is intended only for…- Use CPT Modifier -80 when a physician (MD or DO) serves as an assistant surgeon and provides full, continuous assistance throughout the entire operative procedure; append -80 to the surgical CPT…
    22Modifier –22 (Increased Procedural Services) is used when a reported procedure is substantially more extensive than normally required. The CPT Manual and CMS state it may be appended only when the…- When to use: Append modifier -22 to a procedural CPT code when the service performed is substantially more extensive than the usual service described by that code — i.e., the procedure required…
    52Modifier ‑52 (Reduced Services) indicates that a service or procedure was partially reduced or omitted at the provider’s discretion, allowing reporting of the basic procedure number with a qualifier…- Use modifier -52 when a physician or qualified health professional electively reduces or omits part of a procedure or service (for example, performing fewer required views or omitting a portion of…
    53Modifier 53 (Discontinued Procedure) signals that a surgical or diagnostic service was begun by the physician but terminated because of extenuating circumstances that threatened the patient’s…- Use modifier -53 when a physician/qualified healthcare professional has started a surgical or diagnostic procedure (e.g., anesthesia administered, incision or scope insertion) and then discontinues…

    Related Provider Taxonomies

    8 rows

    Taxonomy Code
    207ZP0102X
    207ZP0105X
    207L00000X
    261QR0401X
    171100000X
    225CX0006X
    1223D0004X
    207VC0200X

    Related ICD-10-CM Codes

    34 rows

    ICD-10-CM CodeDescription
    C17.0–C17.9
    C18.0–C19
    C18.9Malignant neoplasm of colon, unspecified
    C20Malignant neoplasm of rectum
    C21.1Malignant neoplasm of anal canal
    C21.2Malignant neoplasm of cloacogenic zone
    C21.8Malignant neoplasm of overlapping sites of rectum, anus and anal canal
    C22.0Liver cell carcinoma
    C25.9Malignant neoplasm of pancreas, unspecified
    C34.90Malignant neoplasm of unspecified part of unspecified bronchus or lung

    Showing 1–10 of 34

    Related Payer Policy Updates

    Specialty: Genetic & Molecular Testing1 / 3

    10 rows

    PolicyPayerEffective Date
    Minimal Residual Disease (MRD) Testing for Cancerregence2027-01-01
    Biomarker Testing MandateBlue Cross Blue Shield - Rhode Island2027-01-01
    Prenatal (Fetal) Diagnostic TestingBlue Cross Blue Shield - Rhode Island2027-01-01
    Oral Cancer Screening and TestingOscar Health2027-01-01
    RTM Testing for Alpha-1 Antitrypsin DeficiencyOscar Health2027-01-01
    Cytochrome P450 Genotype-Guided Treatment Strategy Corporate Medical Policybcbsvermont2027-01-01
    Cytochrome P450 Genotypingblue cross blue shield - tennessee2026-12-31
    Polygenic Risk ScoreBlue Cross Blue Shield - Rhode Island2026-12-01
    Gene Expression Profiling for Cutaneous MelanomaBlue Cross Blue Shield - Rhode Island2026-12-01
    Chromosomal Microarray Testing for the Evaluation of Pregnancy Lossblue_shield_of_california2026-11-01

    Related Codes

    CPT-81410-GENOMIC-PANEL-AORTIC-DISEASE

    CPT 81410: Heritable Thoracic Aortic Disease Targeted Gene Panel

    CPT-81411-GENETIC-DUPLICATION-DELETION-PANEL-AORTIC-DISEASE

    CPT 81411: Genetic Panel for Aortic Dysfunction Copy Number Analysis

    CPT-81412-ASHKENAZI-JEWISH-GENOMIC-SEQUENCE-PANEL

    CPT 81412: Ashkenazi Jewish–Associated Genetic Sequence Panel

    CPT-81413-GENOMIC-PANEL-CARDIAC-ION-CHANNELOPATHIES

    CPT 81413: Cardiac Ion Channelopathy Targeted Gene Panel

    CPT-81414-CARDIAC-ION-CHANNELOPATHY-CNV-PANEL

    CPT 81414: Cardiac Ion Channelopathy Copy Number Variant Panel

    CPT-81415-EXOME-SEQUENCE-ANALYSIS-UNEXPLAINED-DISORDER

    CPT 81415: Exome Sequence Analysis for Unexplained Disorder

    CPT-81416-FAMILIAL-EXOME-SEQUENCE-ANALYSIS

    CPT 81416: Relative Exome Sequence Analysis for Reference Exome

    CPT-81417-EXOME-SEQUENCE-REEVALUATION

    CPT 81417: Exome Reanalysis for New Clinical Information

    CPT-81418-PHARMACOGENOMIC-MULTIGENE-DRUG-METABOLISM-PANEL

    CPT 81418: Pharmacogenetic Multigene Panel Including CYP2C19 and CYP2D6

    CPT-81419-GENOMIC-SEQUENCE-PANEL-EPILEPSY

    CPT 81419: Genomic Sequence Analysis Panel for Epilepsy

    Showing 1–10 of 43

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

    81450Genomic sequencing panel, hematolymphoid neoplasm (DNA and possibly RNA, 5-50 genes)Not typically for solid tumors but may be referenced when hematolymphoid neoplasm testing is needed in differential diagnoses.
    81451Genomic sequencing panel, hematolymphoid neoplasm, RNA analysis (5-50 genes)RNA-focused panel for hematolymphoid neoplasms; analogous methodology to 81449 but different clinical indication.
    81455Genomic sequencing panel, solid organ neoplasm, DNA (51+ genes)Larger DNA panels that may be ordered when broader genomic coverage is required beyond 50 genes.
    81456Genomic sequencing panel, solid organ neoplasm, RNA (51+ genes)Larger RNA panels for comprehensive fusion/splice variant detection when more than 50 genes are interrogated; alternative to 81449 for expanded testing.